NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization
NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization
PARAMUS, N.J., July 10, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced that its Board of Directors has appointed a new President at its US headquarters. Yukiteru Sugiyama, Ph.D. replaces retiring president Tsugio Tanaka, MSc as of June 30, 2024.
2024年7月10日，尼普顺药业有限公司（Nippon Shinyaku）下属子公司NS Pharma, Inc.（NS Pharma）宣布，其董事会已经任命新总裁负责该公司的美国总部。博士Yukiteru Sugiyama取代退休的Tsugio Tanaka，MSc，自2024年6月30日起。
"As president, it is my mission to maintain heightened levels of empathy at NS Pharma."
“作为总裁，我致力于在NS Pharma保持更高程度的同情心。”
Sugiyama received a doctorate degree in organic chemistry from Nagoya University in 1996. From 1996 until 2007, he worked in research and clinical development with Nippon Shinyaku in Japan, focusing on structural chemistry and blood cancer therapies. In 2007, he transitioned to the commercial division within the company.
1996年，Sugiyama在名古屋大学获得有机化学博士学位。从1996年到2007年，他在尼普顺药业工作，专注于结构化学和血液癌症治疗的研究和临床开发。2007年，他转到了公司的商业部门。
In 2020, during the COVID-19 pandemic, Sugiyama transferred to NS Pharma in the US to work as assistant vice president overseeing commercial functions for VILTEPSO(viltolarsen). In total, Sugiyama has worked for 28 years at Nippon Shinyaku with progressive levels of responsibility.
2020年新冠疫情期间，Sugiyama转移到NS Pharma在美国工作，担任副总裁，负责VILTEPSO(viltolarsen)商业职能。总的来说，Sugiyama在尼普顺药业工作了28年，承担了日益增加的职责。
"Having served in both our science and patient focused fields, I have come to understand that having empathy for the patient is critical in the development of therapies to treat rare diseases," Sugiyama explained. "As president, it is my mission to maintain heightened levels of empathy at NS Pharma, and to enhance transparency between all stakeholders."
Sugiyama解释说：“在我们的科学和以患者为中心的领域任职之后，我明白同情病人对于开发治疗罕见病是至关重要的。作为总裁，我的使命是在NS Pharma保持更高的同情心水平，并增强所有利益相关者之间的透明度。”
Sugiyama will lead the company through the next phases of clinical and commercial development for VILTEPSO and CAP-1002 (through a partnership with Capricor Therapeutics) – for the treatment of Duchenne muscular dystrophy (Duchenne). NS Pharma is also currently working on an exon 44 skipping therapy (Phase 2) and an exon 50 skipping therapy (Phase 1/2) for Duchenne, a selective JAK1 inhibition therapy for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), as well as several preclinical neurological therapies.
Sugiyama将领导公司在VILTEPSO和CAP-1002（与Capricor Therapeutics合作）方面的临床和商业发展的下一个阶段——治疗肌萎缩性侧索硬化症（Duchenne）。NS Pharma目前正在进行外显子44跳过疗法（第2阶段）和外显子50跳过疗法（第1/2阶段）的Duchenne治疗，以及选择性JAK1抑制剂治疗嗜酸性粒细胞肉芽肿性多血管炎（EGPA）的几种临床前神经疾病治疗。
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. NS Pharma is a registered trademark of the Nippon Shinyaku Co., Ltd. For more information, please visit nspharma.com.
关于NS Pharma, Inc.
NS Pharma, Inc.是尼普顺药业有限公司（Nippon Shinyaku Co.，Ltd）的全资子公司。NS Pharma是尼普顺药业有限公司的注册商标。欲了解更多信息，请访问nspharma.com。
US Media Contact:
[email protected]
美国媒体联络:
[email protected]
SOURCE NS Pharma, Inc.
消息来源: NS Pharma, Inc.